Indication
Malignant Genitourinary System Neoplasm
2 clinical trials
4 products
Clinical trial
A Phase 1 Study of Cabozantinib Plus Nivolumab (CaboNivo) Alone or in Combination With Ipilimumab (CaboNivoIpi) in Patients With Advanced/Metastatic Urothelial Carcinoma and Other Genitourinary TumorsStatus: Active (not recruiting), Estimated PCD: 2024-09-30
Product
CabozantinibProduct
IpilimumabProduct
NivolumabClinical trial
Fecal Microbiota Transplantation (FMT) for Immune-Checkpoint Inhibitor Induced-Diarrhea/Colitis in Genitourinary Cancer PatientsStatus: Recruiting, Estimated PCD: 2025-12-31
Product
Loperamide